291 related articles for article (PubMed ID: 29984302)
1. HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.
Ghosh AK; Sarkar A; Mitsuya H
Med Res Arch; 2017 Apr; 5(4):. PubMed ID: 29984302
[TBL] [Abstract][Full Text] [Related]
2. Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-Resistant HIV-1 and Favorable Blood-Brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors
Amano M; Yedidi RS; Salcedo-Gómez PM; Hayashi H; Hasegawa K; Martyr CD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0171521. PubMed ID: 34978889
[TBL] [Abstract][Full Text] [Related]
3. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
[TBL] [Abstract][Full Text] [Related]
4. Beneficial and Adverse Effects of cART Affect Neurocognitive Function in HIV-1 Infection: Balancing Viral Suppression against Neuronal Stress and Injury.
Yuan NY; Kaul M
J Neuroimmune Pharmacol; 2021 Mar; 16(1):90-112. PubMed ID: 31385157
[TBL] [Abstract][Full Text] [Related]
5. HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment.
Saylor D; Dickens AM; Sacktor N; Haughey N; Slusher B; Pletnikov M; Mankowski JL; Brown A; Volsky DJ; McArthur JC
Nat Rev Neurol; 2016 Apr; 12(4):234-48. PubMed ID: 26965674
[TBL] [Abstract][Full Text] [Related]
6. HIV-associated neurocognitive disorder and HIV-associated myelopathy in a patient with a preserved CD4, but high viral load-a rarely reported phenomenon: a case report and literature review.
Ayele BA; Amogne W; Gemechu L
BMC Infect Dis; 2020 Aug; 20(1):574. PubMed ID: 32758161
[TBL] [Abstract][Full Text] [Related]
7. Interrogating the impact of combination antiretroviral therapies on HIV-associated neurocognitive disorders.
Sharma I
HIV Med; 2021 Oct; 22(9):783-790. PubMed ID: 34291558
[TBL] [Abstract][Full Text] [Related]
8. Changing clinical phenotypes of HIV-associated neurocognitive disorders.
Sacktor N
J Neurovirol; 2018 Apr; 24(2):141-145. PubMed ID: 28752495
[TBL] [Abstract][Full Text] [Related]
9. Neuropathology of HAND With Suppressive Antiretroviral Therapy: Encephalitis and Neurodegeneration Reconsidered.
Gelman BB
Curr HIV/AIDS Rep; 2015 Jun; 12(2):272-9. PubMed ID: 25860316
[TBL] [Abstract][Full Text] [Related]
10. Developments in Neuroprotection for HIV-Associated Neurocognitive Disorders (HAND).
Kolson DL
Curr HIV/AIDS Rep; 2022 Oct; 19(5):344-357. PubMed ID: 35867211
[TBL] [Abstract][Full Text] [Related]
11. Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients.
Weichseldorfer M; Reitz M; Latinovic OS
Pharmaceutics; 2021 Oct; 13(11):. PubMed ID: 34834213
[TBL] [Abstract][Full Text] [Related]
12. HIV-associated neurocognitive disorders: Five new things.
Rumbaugh JA; Tyor W
Neurol Clin Pract; 2015 Jun; 5(3):224-231. PubMed ID: 26124979
[TBL] [Abstract][Full Text] [Related]
13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
14. Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience.
Arendt G; Schlonies S; Orhan E; Stüve O
J Neurovirol; 2019 Apr; 25(2):174-182. PubMed ID: 30628025
[TBL] [Abstract][Full Text] [Related]
15. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
16. Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction.
Duran-Castells C; Llano A; Kawana-Tachikawa A; Prats A; Martinez-Zalacain I; Kobayashi-Ishihara M; Oriol-Tordera B; Peña R; Gálvez C; Silva-Arrieta S; Clotet B; Riveira-Muñoz E; Ballana E; Prado JG; Martinez-Picado J; Sanchez J; Mothe B; Hartigan-O'Connor D; Wyss-Coray T; Meyerhans A; Gisslén M; Price RW; Soriano-Mas C; Muñoz-Moreno JA; Brander C; Ruiz-Riol M
J Virol; 2023 Feb; 97(2):e0165522. PubMed ID: 36719240
[TBL] [Abstract][Full Text] [Related]
17. Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.
Clark US; Cohen RA
Curr Opin Investig Drugs; 2010 Aug; 11(8):884-900. PubMed ID: 20721831
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro.
Gavegnano C; Haile WB; Hurwitz S; Tao S; Jiang Y; Schinazi RF; Tyor WR
J Neuroinflammation; 2019 Sep; 16(1):182. PubMed ID: 31561750
[TBL] [Abstract][Full Text] [Related]
19. Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model.
Koneru R; Olive MF; Tyor WR
J Neurovirol; 2014 Feb; 20(1):9-17. PubMed ID: 24415129
[TBL] [Abstract][Full Text] [Related]
20. Evolving clinical phenotypes in HIV-associated neurocognitive disorders.
Sacktor N; Robertson K
Curr Opin HIV AIDS; 2014 Nov; 9(6):517-20. PubMed ID: 25203640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
